UNSPSC 51171840: Hyoscine or levo-duboisine or scopolamine

This classification denotes a mydriatic agent and antimuscarinic agent with the molecular formula C17H21NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DL48G20X8X, chemically known as 1.alpha.h, 5.alpha.h-tropan-3.alpha.-ol, 6.beta.,7.beta.-epoxy-, (-)-tropate (ester), hydrobromide but generally known as hyoscine, which bears US NIH Compound Identifier 5184. European Medicines Agency schedules Hyoscine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14152MIG.

World Health Organization schedules hyoscine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: O1C2C1C1N(C2CC(OC(=O)C(CO)C2CCCCC2)C1)C.

UNSPSC 51171840 Hyoscine or levo-duboisine or scopolamine is a Commodity code showing minimal recent activity in state and local procurement aligned with its nominal pharmaceutical scope. The single recent opportunity in the dataset—Collin County Community Supervision and Corrections Department RFP 2026-327 for offender specimen collection and drug testing services—does not involve procurement of scopolamine or related compounds. Instead, the work encompasses staffing two collection sites in Plano and McKinney, operating an Interactive Voice Response system for randomized testing notifications, conducting immunoassay screening with LC/MS/MS or GC/MS confirmation, and performing alternative testing via oral fluid and hair analysis. The estimated contract value is $600,000 over two years with three optional one-year renewals. The scope is misaligned with the code's pharmaceutical scope, suggesting either a taxonomic classification error on the county's part or that this code does not reflect actual state and local procurement demand for the named pharmaceutical compounds.

The geographic footprint is limited to Texas based on available records. Collin County issued the RFP on September 25, 2026, with proposals due July 23, 2026 (an inconsistent date sequence in the source); the anticipated award date is August 10, 2026. The county may award in whole or in part to multiple vendors and requires lab certification from SAMHSA, TX DPS, or CAP. Pricing is submitted per-test across three models (screening only, confirmation after screening, and screening with automatic confirmation of positives), with price reductions mandated if the vendor offers lower rates to other customers and redetermination requests limited to September 1 anniversaries with increases capped at 3.0 percent annually based on medical Consumer Price Index adjustments. Evaluation emphasizes vendor understanding (30 points), firm qualifications (25 points), client references (15 points), and cost (30 points), with optional Phase 2 demonstrations and interviews worth up to 30 points.